Vanguard Asset Management
ZBIO

Vanguard Asset Management’s Zenas BioPharma ZBIO Stock Holding History

Vanguard Asset Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$523K Buy
20,623
+9,981
+94% +$198K ﹤0.01% 2167
2026
Q1 		$208K Buy
+10,642
New +$239K ﹤0.01% 2358

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Asset Management's ZBIO Position: Q2 2026 in Review

Vanguard Asset Management increased its Zenas BioPharma (ZBIO) stake by 94% in Q2 2026, buying an estimated $198K and bringing the position to 20,623 shares worth $523K. The position accounts for ﹤0.01% of the portfolio, ranked #2167.

Vanguard Asset Management first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 132 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Vanguard Asset Management held 20,623 shares of Zenas BioPharma worth $523K as of Q2 2026.
  • Vanguard Asset Management bought 9,981 Zenas BioPharma shares in Q2 2026, an estimated $198K.
  • Zenas BioPharma made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2167 holding.
  • Vanguard Asset Management first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 132 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.